José Damas, Aline Munting, Jacques Fellay, David Haerry, Catia Marzolini, Philip E Tarr, Ana Steffen, Dominique L Braun, Marcel Stoeckle, Enos Bernasconi, Olivier Nawej Tshikung, Christoph A Fux, Katharine E A Darling, Charles Béguelin, Gilles Wandeler, Matthias Cavassini, Bernard Surial
BACKGROUND: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). While weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study. METHODS: We included participants who received at least six months of TAF-containing ART between January 2016 and March 2023...
April 12, 2024: Clinical Infectious Diseases